The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action

Kristine J Hare; Tina Vilsbøll; Meena Asmar; Carolyn F Deacon; Filip K Knop; Jens Juul Holst

doi:10.2337/db09-1414

The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action

Kristine J Hare, Tina Vilsbøll, Meena Asmar, Carolyn F Deacon, Filip K Knop, Jens Juul Holst

Research output: Contribution to journal › Journal article › Research › peer-review

234 Citations (Scopus)

Abstract

Glucagon-like peptide 1 (GLP-1) exerts beneficial antidiabetic actions via effects on pancreatic beta- and alpha-cells. Previous studies have focused on the improvements in beta-cell function, while the inhibition of alpha-cell secretion has received less attention. The aim of this research was to quantify the glucagonostatic contribution to the glucose-lowering effect of GLP-1 infusions in patients with type 2 diabetes.

Original language	English
Journal	Diabetes
Volume	59
Issue number	7
Pages (from-to)	1765-70
Number of pages	6
ISSN	0012-1797
DOIs	https://doi.org/10.2337/db09-1414
Publication status	Published - 1 Jul 2010

Keywords

Adult
Analysis of Variance
Area Under Curve
Blood Glucose
Diabetes Mellitus, Type 2
Glucagon
Glucagon-Like Peptide 1
Glucose Clamp Technique
Humans
Insulin
Male
Middle Aged
Time Factors
Treatment Outcome

Access to Document

10.2337/db09-1414

Cite this

The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action. / Hare, Kristine J; Vilsbøll, Tina; Asmar, Meena; Deacon, Carolyn F ; Knop, Filip K ; Holst, Jens Juul.

In: Diabetes, Vol. 59, No. 7, 01.07.2010, p. 1765-70.

Research output: Contribution to journal › Journal article › Research › peer-review

@article{87f0d1dbe1de46d09ec4ea166280e402,

title = "The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action",

abstract = "Glucagon-like peptide 1 (GLP-1) exerts beneficial antidiabetic actions via effects on pancreatic beta- and alpha-cells. Previous studies have focused on the improvements in beta-cell function, while the inhibition of alpha-cell secretion has received less attention. The aim of this research was to quantify the glucagonostatic contribution to the glucose-lowering effect of GLP-1 infusions in patients with type 2 diabetes.",

keywords = "Adult, Analysis of Variance, Area Under Curve, Blood Glucose, Diabetes Mellitus, Type 2, Glucagon, Glucagon-Like Peptide 1, Glucose Clamp Technique, Humans, Insulin, Male, Middle Aged, Time Factors, Treatment Outcome",

author = "Hare, {Kristine J} and Tina Vilsb{\o}ll and Meena Asmar and Deacon, {Carolyn F} and Knop, {Filip K} and Holst, {Jens Juul}",

year = "2010",

month = jul,

day = "1",

doi = "10.2337/db09-1414",

language = "English",

volume = "59",

pages = "1765--70",

journal = "Diabetes",

issn = "0012-1797",

publisher = "American Diabetes Association",

number = "7",

}

TY - JOUR

T1 - The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action

AU - Hare, Kristine J

AU - Vilsbøll, Tina

AU - Asmar, Meena

AU - Deacon, Carolyn F

AU - Knop, Filip K

AU - Holst, Jens Juul

PY - 2010/7/1

Y1 - 2010/7/1

N2 - Glucagon-like peptide 1 (GLP-1) exerts beneficial antidiabetic actions via effects on pancreatic beta- and alpha-cells. Previous studies have focused on the improvements in beta-cell function, while the inhibition of alpha-cell secretion has received less attention. The aim of this research was to quantify the glucagonostatic contribution to the glucose-lowering effect of GLP-1 infusions in patients with type 2 diabetes.

AB - Glucagon-like peptide 1 (GLP-1) exerts beneficial antidiabetic actions via effects on pancreatic beta- and alpha-cells. Previous studies have focused on the improvements in beta-cell function, while the inhibition of alpha-cell secretion has received less attention. The aim of this research was to quantify the glucagonostatic contribution to the glucose-lowering effect of GLP-1 infusions in patients with type 2 diabetes.

KW - Adult

KW - Analysis of Variance

KW - Area Under Curve

KW - Blood Glucose

KW - Diabetes Mellitus, Type 2

KW - Glucagon

KW - Glucagon-Like Peptide 1

KW - Glucose Clamp Technique

KW - Humans

KW - Insulin

KW - Male

KW - Middle Aged

KW - Time Factors

KW - Treatment Outcome

U2 - 10.2337/db09-1414

DO - 10.2337/db09-1414

M3 - Journal article

C2 - 20150286

VL - 59

SP - 1765

EP - 1770

JO - Diabetes

JF - Diabetes

SN - 0012-1797

IS - 7

ER -